Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Autor:
Nassim Ledoux, William-Naud Gauthier, Pauline Adjibade, Edouard W. Khandjian, Bryan Simoneau, Rachid Mazroui, Melisse Nkurunziza
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 5, p e0231894 (2020)
PLoS ONE, Vol 15, Iss 5, p e0231894 (2020)
Stress granules (SG) are cytoplasmic RNA granules that form during various types of stress known to inhibit general translation, including oxidative stress, hypoxia, endoplasmic reticulum stress (ER), ionizing radiations or viral infection. Induction
Autor:
Yeonhee Park, Antonio Giordano, Stephen P. Ethier, Kent Armeson, James M. Reuben, Carolyn D. Britten, Elizabeth S. Yeh, Mark G. Erlander, Christiana S. Kappler, Maya Ridinger, Y Liu
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 11, p e0224420 (2019)
PLoS ONE, Vol 14, Iss 11, p e0224420 (2019)
Within triple negative breast cancer, several molecular subtypes have been identified, underlying the heterogeneity of such an aggressive disease. The basal-like subtype is characterized by mutations in the TP53 gene, and is associated with a low pat
Autor:
Yun Fu, Sheng Guo, Changzheng Li, Tiesuo Zhao, Yun Yang, Yanjie Sun, Yongli Li, Tengfei Huang, Tingting Wang
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 9, p e0215886 (2019)
PLoS ONE, Vol 14, Iss 9, p e0215886 (2019)
The progression of cancer through local expansion and metastasis is well recognized, but preventing these characteristic cancer processes is challenging. To this end, a new strategy is required. In this study, we presented a novel dual functional pod
Autor:
Patrick Michl, Jan-Philipp Mordhorst, Katharina Theuerkorn, Thomas M. Gress, Anja Rinke, Sebastian Krug, Maren Egidi, Fabian Moser, Claudia Ruffert
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 6, p e0218953 (2019)
PLoS ONE, Vol 14, Iss 6, p e0218953 (2019)
Somatostatin analogues (SSA) represent the standard of care for symptom control in patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In addition, SSA exert significant anti-proliferative effects in mid-gut and pancrea
Autor:
Subash C. Jonnalagadda, Chun Wu, Abhinav Illendula, Norman Fultang, Zachary Klase, Brian Y. Chen, Bela Peethambaran, Nathan J. Baird
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 5, p e0217789 (2019)
PLoS ONE, Vol 14, Iss 5, p e0217789 (2019)
Triple Negative Breast Cancer (TNBC), the most aggressive subtype of breast cancer, is characterized by the absence of hormone receptors usually targeted by hormone therapies like Tamoxifen. Because therapy success and survival rates for TNBC lag far
Autor:
L. Nevi, Gian Luca Grazi, D. Costantini, Vincenzo Cardinale, S. Safarikia, Alessandra Giorgi, Chiara Napoletano, E. Manzi, Luciano Adorini, A. M. De Rose, Domenico Alvaro, Felice Giuliante, S. Di Matteo, Diletta Overi, Fabio Melandro, Guido Carpino, Eugenio Gaudio, M.C. Bragazzi, P.B. Berloco, F. Giulitti
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210077 (2019)
PLoS ONE
PLoS ONE
Cholangiocarcinoma (CCA) is an aggressive cancer with high resistance to chemotherapeutics. CCA is enriched in cancer stem cells, which correlate with aggressiveness and prognosis. FXR, a member of the metabolic nuclear receptor family, is markedly d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0660502a6d45ad79d748d93079d000
http://hdl.handle.net/11573/1233660
http://hdl.handle.net/11573/1233660
Autor:
Jake Moscarelli, Z. Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, Smith Giri, Amy Xiong, Elena Ratner, Pamela H Huang, Yasmin Korayem, Patricia LoRusso
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 11, p e0207399 (2018)
PLoS ONE, Vol 13, Iss 11, p e0207399 (2018)
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of th
Autor:
Joanna Dutko-Gwozdz, Omar N. Pathmanaban, Peter Cueppens, Kenny Yu, Brian A. Telfer, Gareth Griffiths, Ian Peers, Roderick Benson, Kaye J. Williams, Brian W. Bigger, Deniz Beyit, Catherine McBain, Ian Kamaly-Asl, Amir Saam Youshani, Jessica T. Taylor
Publikováno v:
PLoS ONE
Yu, K K H, Taylor, J T, Pathmanaban, O N, Youshani, A S, Beyit, D, Dutko-Gwozdz, J, Benson, R, Griffiths, G, Peers, I, Cueppens, P, Telfer, B A, Williams, K J, McBain, C, Kamaly-Asl, I D & Bigger, B W 2018, ' High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma ', PLoS ONE, vol. 13, no. 3, e0193694 . https://doi.org/10.1371/journal.pone.0193694
PLoS ONE, Vol 13, Iss 3, p e0193694 (2018)
Yu, K K H, Taylor, J T, Pathmanaban, O N, Youshani, A S, Beyit, D, Dutko-Gwozdz, J, Benson, R, Griffiths, G, Peers, I, Cueppens, P, Telfer, B A, Williams, K J, McBain, C, Kamaly-Asl, I D & Bigger, B W 2018, ' High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma ', PLoS ONE, vol. 13, no. 3, e0193694 . https://doi.org/10.1371/journal.pone.0193694
PLoS ONE, Vol 13, Iss 3, p e0193694 (2018)
Background Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes remain poor. First line treatment is well established, however disease invariably recurs and improving prognosis is challenging. With the aim o
Autor:
María José Ruiz-Hidalgo, Antonio S. Salinas, Marta Ortega-Muelas, Ricardo Sánchez-Prieto, José M. Giménez-Bachs, Raquel Pascual-Serra, Francisco J. Cimas, Maria Ll. Valero, Diego M. Fernández-Aroca, Olga Roche, Borja Belandia, Jesús García-Cano, Leticia Serrano-Oviedo
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
PLoS ONE, Vol 13, Iss 7, p e0200878 (2018)
PLoS ONE
instname
PLoS ONE, Vol 13, Iss 7, p e0200878 (2018)
PLoS ONE
[Objectives]: To fully clarify the role of Mitogen Activated Protein Kinase in the therapeutic response to Sorafenib in Renal Cell Carcinoma as well as the cell death mechanism associated to this kinase inhibitor, we have evaluated the implication of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f61a328e682755483b98f2fb7c369535
http://hdl.handle.net/10261/188039
http://hdl.handle.net/10261/188039
Autor:
Peter Y. Yu, Lucia Casadei, Gonzalo Lopez, Edwin Choy, Kara Batte, Danielle Braggio, Obiajulu H. Iwenofu, Dina Lev, Raphael E. Pollock, Anne M. Strohecker, David Koller, Abeba Zewdu, Hemant Kumar Bid
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 11, p e0188859 (2017)
PLoS ONE, Vol 12, Iss 11, p e0188859 (2017)
Leiomyosarcoma (LMS) is a malignant soft tissue sarcoma (STS) with a dismal prognosis following metastatic disease. Chemotherapeutic intervention has demonstrated to have modest clinical efficacy with no curative potential in LMS patients. Previously